Septerna (SEPN) – Investment Analysts’ Recent Ratings Updates

Septerna (NASDAQ: SEPN) recently received a number of ratings updates from brokerages and research firms:

• 3/14/2026 – Septerna was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/11/2026 – Septerna had its price target raised by Truist Financial Corporation from $34.00 to $35.00. They now have a “buy” rating on the stock.
• 3/10/2026 – Septerna had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $60.00 price target on the stock.
• 3/3/2026 – Septerna had its price target raised by Wells Fargo & Company from $28.00 to $48.00. They now have an “overweight” rating on the stock.
• 3/2/2026 – Septerna had its price target raised by HC Wainwright from $35.00 to $40.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Septerna was upgraded by Zacks Research from “strong sell” to “hold”.
• 1/23/2026 – Septerna was downgraded by Zacks Research from “hold” to “strong sell”.
• 1/22/2026 – Septerna had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Septerna

In related news, insider Samira Shaikhly sold 70,453 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $28.10, for a total value of $1,979,729.30. Following the completion of the sale, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total transaction of $115,880.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. The trade was a 2.24% decrease in their position. The SEC filing for this sale provides additional information. 4.30% of the stock is owned by insiders.

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.